{
    "clinical_study": {
        "@rank": "136223", 
        "arm_group": {
            "arm_group_label": "Exemestane", 
            "arm_group_type": "Experimental", 
            "description": "Exemestane 25 mg daily"
        }, 
        "brief_summary": {
            "textblock": "A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma\n\n      Hypothesis: Treatment With Exemestane can give a response rate of at least 30%"
        }, 
        "brief_title": "Exemestane in Advanced and Recurrent Endometrial Carcinoma", 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": "Endometrial Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Endometrial Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated\n      With Exemestane tablets 25 mg daily.\n\n      Patients were grouped according to estrogen receptor status."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced or recurrent endometrial cancer not considered for treatment modalities\n             apart from hormonal treatment\n\n          -  Endometrioid histology\n\n          -  Age above 18 years\n\n          -  Post menopausal status\n\n          -  Performance status 0-2\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Congestive heart disease grade III.IV\n\n          -  History of thromboembolic signs\n\n          -  Other primary hormonal therapy\n\n          -  Patients With symptomatic brain metastasis\n\n          -  Severe hepatic or renal impairment\n\n          -  Pregnancy, lactation or child bearing potential without adequate contraception"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965080", 
            "org_study_id": "NSGO-EC-0302"
        }, 
        "intervention": {
            "arm_group_label": "Exemestane", 
            "description": "One tablet Exemestane 25 mg daily", 
            "intervention_name": "Exemestane", 
            "intervention_type": "Drug", 
            "other_name": "Aromasin"
        }, 
        "intervention_browse": {
            "mesh_term": "Exemestane"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Endometrial cancer", 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway", 
                    "zip": "0310"
                }, 
                "name": "The Norwegian Radium Hospital"
            }
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma", 
        "other_outcome": {
            "description": "Asses toxicity to the treatment using Common Toxicity Criteria for Adverse Effects", 
            "measure": "Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 years"
        }, 
        "overall_official": {
            "affiliation": "NSGO", 
            "last_name": "Gunnar Kristensen, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Norway: Norwegian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Objective response rate within 6 months of treatment", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965080"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Special attention to progression status at 6 months", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Nordic Society for Gynaecologic Oncology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nordic Society for Gynaecologic Oncology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2004", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}